Acrux History

Acrux incorporated

First US patent granted

Veterinary licensed to Elanco globally (including Recuvyra^®)

Acrux listed on ASX (ACR:ASX)

Evamist^® licensed to KV Pharmaceutical in US

Evamist^® launched by KV Pharmaceutical

Acrux initiates Axiron^® Phase III clinical trial

Acrux submits Axiron^® NDA to FDA

Axiron^® licensed to Eli Lilly globally

Axiron^® launched by Eli Lilly

Recuvyra^® launched by Elanco

Estradiol licensed to Gedeon Richter; including for EU

Evamist^® licensed to Perrigo in US

Initiated generic programs

Lenzetto^® launched in Europe

Active pipeline of 10 generic products.

Axiron^® was withdrawn from the US market on 5th of September 2017 due to the launch of generic versions.

Submitted first two ANDA (generic) products to the FDA for review

Submitted third ANDA (generic) product to the FDA for review.

Active pipeline of 14 generic products.